JATT Acquisition Corp. (NYSE: JATT) announced this morning that it has closed its combination with biotech firm Zura Bio.
The combined company’s shares and warrants are expected to begin trading on the Nasdaq later today, March 21, under the symbols “ZURA” and “ZURAW”, respectively.
The combination has netted Zura Bio about $65 million in gross cash proceeds, which it will use to advance its existing clinical portfolio and make acquisitions. This funding came primarily in the form of a $50 million PIPE and $15 million in forward purchase agreements.
JATT initially announced its $215 million business combination with Zura Bio in June 2022. London-based Zura Bio is a clinical-stage firm developing novel medicines for immune disorders with an initial focus on alopecia.
Alopecia itself afflicts about 700,000 Americans and 6.8 million have had it at some point in their lifetime, but the same auto-immune blockers that Zura Bio is researching might also be effective against asthma, ulcerative colitis, vitiligo, and type 1 diabetes mellitus among other conditions. Altogether, Zura Bio believes it could have a treatment market of 150 million worth about $100 billion.
- Raymond James & Associates, Inc. and its affiliates (together, “Raymond James”) is acting as the lead PIPE placement agent
- Raymond James & Associates, Inc. is financial advisor to JATT in the transaction.
- McDermott Will & Emery LLP is acting as legal counsel to Zura Bio.
- Ogier is acting as legal counsel to Zura Bio.
- Loeb & Loeb LLP and Simmons & Simmons are acting as legal counsel to JATT
- Maples and Calder (Cayman) LLP are acting as Cayman Islands legal counsel to JATT.
- Paul Hastings LLP is acting as legal counsel to Raymond James.
Latest SPAC Liquidations: JAWS Hurricane JAWS Hurricane Acquisition Corporation (HCNE) to Liquidate on June 16 JAWS Hurricane Acquisition Corporation (Nasdaq: HCNE) today announced that its board of directors has determined not to proceed with a proposal to extend its corporate existence. As such, the Board has determined to cancel the special meeting of its stockholders,...
Jupiter Wellness Acquisition Corp. (NASDAQ:JWAC) announced this afternoon that it has completed its combination with Chinese carmaker Chijet. The deal was already approved by shareholders at a special meeting held on May 2, but at that time, the SPAC did not provide a timeline for the closing of the transaction. Although redemption numbers have still not...
The advent of summer is bringing nine lock-up expirations for de-SPAC’d companies and 10 on the sponsor side. The first change is to come for the sponsor of European Biotech Acquisition Corp., which closed its combination with Swiss pharma firm Oculis SA (NASDAQ:OCS) just three months ago. The sponsor is getting flexibility at a good...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Lucid to raise $3B in a common stock offering from Saudi owners, Betsy Cohen says SPACs will make a comeback, and SatixFy makes another leadership change Lucid Raising $3 Billion With More Money From...
An article on Bloomberg yesterday announced what many in SPAC Land have been wondering after UBS acquired Credit Suisse – where was Niron Stabinsky, the Head of SPACs at Credit Suisse, going to land? The answer is Banco Santander SA, in what appears to be a massive lift of most (or nearly all) of Credit...